Treatment of hepatitis B and C - Current standards;Therapie der hepatitis B und C - Standards 2004

Deutsche Medizinische Wochenschrift

Volumn 129, Issue SUPPL. 2, 2004, Pages

  Zeuzem, Stefan ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; AMINOTRANSFERASE; ANTIVIRUS AGENT; EMTRICITABINE; FAMCICLOVIR; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TENOFOVIR; VIRUS DNA; VIRUS RNA;

ANTIBODY TITER; CLINICAL PROTOCOL; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG INDICATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PRACTICE GUIDELINE; REVIEW; SEROCONVERSION; TREATMENT INDICATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG RESISTANCE, VIRAL; HEPATITIS B; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 4644241414     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-831372     Document Type: Review

References (15)

1. EASL consensus conference panel. Proceedings of the European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis B. J Hepatol 2003; 39 (Suppl 1); S1-235
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marines G, Jr. Goncales FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Huffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
3. Hadziyannis SJ, Jr. Sette H, Morgan TR, Balan V. Diago M, Marcellin P, Ramadori G, Bodenheimer HJr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355
4. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns MP. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452-1457
5. Janssen HLA, Senturk H, Zeuzem S, Akarca U, Cakaloglu Y, Simon K, So Man Kit T, Gerken G, Schalm SW for the HBV 99-01 Study Group. Peginterferon alfa-2b and lamivudine combination therapy compared with peginterferon alfa-2b for chronic HBeAg-positive hepatitis B: a randomized controlled trial in 307 patients (Abstract). Hepatology 2003; 38 (Suppl 1); 246A
6. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, Wright TL. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004; 2: 87-106
7. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001; 120: 1828-1853
8. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
9. Marcellin P, Lau GKK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu Z-M, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Ui M-Y, Button P, Pluck N. A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (4OkD) (Pegasys) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe positive chronic hepatitis B (Abstract). Hepatology 2003; 38 (Suppl 1); 724A
10. National Institutes of Health consensus development conference statement. Management of hepatitis C: 2002. Hepatology 2002; 36 (Suppl); S3-S15
11. Poynard T, Regimbeau C, Myers RP, Thevenot T, Leroy V, Mathurin P, Opolon P, Zarski JP. Interferon for acute hepatitis C. Cochrane Database Syst Rev 2002; 1: CD000369
12. Sarrazin U, Zeuzem S. Therapie der Hepatitis B. Der Kassenarzt 2003; 3: 32-37
13. Sung JJY, Ui JY, Zeuzem S, Chow WC, Heathcote E, Perrillo R. Brosgart C, Woessner M, Scott SA, Campbell FM. A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): week 52 analysis (Abstract). J Hepatol 2003; 38 (Suppl 2); 25
14. Zeuzem S, Diago M, Gane E, Reddy R, Pockros P, Farci P, Gitlin N, Umour F, Lardelli P, Shiffman M. International, multicenter, randomized, controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peginterferon alfa-2a (40 kD) (Pegasys®) and ribavirin (Copegus®) (Abstract). Hepatology 2003; 38 (Suppl 1); 208A
15. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C; who responds less well? Ann Intern Med 2004; 140: 370-381